Lancet regional health. Americas · 2025
A randomised, double-blind, sham-controlled, 2×2 factorial trial of aerobic vs. non-aerobic exercise and motor cortex transcranial direct current stimulation in fibromyalgia: effects on clinical outcomes and descending pain modulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fregni Felipe, Castelo-Branco Luis, Cardenas-Rojas Alejandra, Daibes Marianna, Silva Fernanda Mq, Pacheco-Barrios Kevin, Lacerda Guilherme J M, Camargo Lucas, Gianlorenco Anna Carolyna, Caumo Wolnei
Аннотация
BACKGROUND: Exercise is first-line therapy for fibromyalgia, but the superiority of aerobic vs. non-aerobic modalities is uncertain. Motor-cortex transcranial direct current stimulation (tDCS) may enhance descending pain inhibition. We tested the effects of exercise modality and tDCS on conditioned pain modulation (CPM) and clinical outcomes.
METHODS: Double-blind, randomised 2 × 2 factorial trial in Boston, USA (2019-2024; allocation 1:1:1:1). Adults with fibromyalgia were assigned to aerobic + active tDCS, aerobic + sham, non-aerobic + active, or non-aerobic + sham. Participants completed 16 in-person sessions over 4 weeks, combining concurrent tDCS and exercise. The non-aerobic condition involved light treadmill walking matched for duration but below aerobic threshold (<40% HRmax). Primary outcomes were changes in CPM and temporal summation of pain (TSP) at week 6; secondary outcomes were pain, fatigue, sleep, quality of life, and depressive symptoms.
FINDINGS: Of 116 participants (mean age 47.1 ± 11.9 years), 88.8% were female. Active tDCS improved CPM vs. sham (Cohen's d = 0.66; p = 0.015), independent of exercise modality, and showed a small, nonsignificant improvement in TSP (mean change -0.19 [95% CI -0.90, 0.51]). All groups showed moderate-to-large improvements in pain, fatigue, and quality of life (Cohen's d 0.60-0.92), with no added benefit from tDCS. Non-aerobic and aerobic exercise produced comparable symptom improvements. Greater age and lower body mass index (BMI) were associated with enhanced response. Changes in pain modulation were not mediated by short-term clinical changes.
INTERPRETATION: Supervised aerobic and non-aerobic exercise produced meaningful short-term clinical improvements. Motor-cortex tDCS enhanced descending pain inhibition but did not add clinical benefit beyond exercise over 6 weeks.
FUNDING: National Institutes of health (R01 1R01AT009491-01A1).
METHODS: Double-blind, randomised 2 × 2 factorial trial in Boston, USA (2019-2024; allocation 1:1:1:1). Adults with fibromyalgia were assigned to aerobic + active tDCS, aerobic + sham, non-aerobic + active, or non-aerobic + sham. Participants completed 16 in-person sessions over 4 weeks, combining concurrent tDCS and exercise. The non-aerobic condition involved light treadmill walking matched for duration but below aerobic threshold (<40% HRmax). Primary outcomes were changes in CPM and temporal summation of pain (TSP) at week 6; secondary outcomes were pain, fatigue, sleep, quality of life, and depressive symptoms.
FINDINGS: Of 116 participants (mean age 47.1 ± 11.9 years), 88.8% were female. Active tDCS improved CPM vs. sham (Cohen's d = 0.66; p = 0.015), independent of exercise modality, and showed a small, nonsignificant improvement in TSP (mean change -0.19 [95% CI -0.90, 0.51]). All groups showed moderate-to-large improvements in pain, fatigue, and quality of life (Cohen's d 0.60-0.92), with no added benefit from tDCS. Non-aerobic and aerobic exercise produced comparable symptom improvements. Greater age and lower body mass index (BMI) were associated with enhanced response. Changes in pain modulation were not mediated by short-term clinical changes.
INTERPRETATION: Supervised aerobic and non-aerobic exercise produced meaningful short-term clinical improvements. Motor-cortex tDCS enhanced descending pain inhibition but did not add clinical benefit beyond exercise over 6 weeks.
FUNDING: National Institutes of health (R01 1R01AT009491-01A1).